Getting to the (germinal) center of humoral immune responses to SARS-CoV-2

Stuart G Tangye; Deborah L Burnett; Rowena A Bull

doi:10.1016/j.cell.2022.02.018

Getting to the (germinal) center of humoral immune responses to SARS-CoV-2

Cell. 2022 Mar 17;185(6):945-948. doi: 10.1016/j.cell.2022.02.018.

Authors

Stuart G Tangye¹, Deborah L Burnett², Rowena A Bull³

Affiliations

¹ Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW Sydney, Darlinghurst, NSW, Australia. Electronic address: s.tangye@garvan.org.au.
² Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW Sydney, Darlinghurst, NSW, Australia.
³ School of Medical Sciences, Faculty of Medicine and Health, UNSW Sydney, Kensington, NSW, Australia; The Kirby Institute, UNSW Sydney, Kensington, New South Wales, Australia.

Abstract

Long-term protection against SARS-CoV-2 requires effective and durable immunity. In this issue of Cell, two papers closely examine germinal centers, the physiological birthplace of adaptive immunity, to quantify the specificity, breadth, magnitude, and persistence of systemic and local humoral immune responses following natural infection with, or vaccination against, SARS-CoV-2.

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
COVID-19*
Germinal Center
Humans
Immunity, Humoral*
SARS-CoV-2

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines